Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2025-12-25 @ 9:57 PM
Study NCT ID:
NCT03140358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-18
First Post:
2017-05-02
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)
Sponsor:
Singapore National Eye Centre
Organization:
Study Overview
Official Title:
The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.
Detailed Description:
High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: